A novel llama antibody targeting Fn14 exhibits anti-metastatic activity in vivo

mAbs

Volumn 6, Issue 1, 2014, Pages 297-308

  Trebing, Johannes ^a   Lang, Isabell ^a   Chopra, Martin ^a   Salzmann, Steffen ^a   Moshir, Mahan ^b   Silence, Karen ^b   S Riedel, Simone ^a   Siegmund, Daniela ^a   Beilhack, Andreas ^a   Otto, Christoph ^a   Wajant, Harald ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b ArGEN X BVBA   (Belgium)

Author keywords

Antibody dependent cellular cytotoxicity; Camelid antibodies; Fc ; Fn14; Metastases; Receptor; TWEAK

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOKINE; FC RECEPTOR; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR INDUCIBLE 14; GAMMA INTERFERON; I KAPPA B; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G1 ANTIBODY; INTERLEUKIN 8; LLAMA ANTIBODY; TUMOR NECROSIS FACTOR LIKE WEAK INDUCER OF APOPTOSIS; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE DESTRUCTION; CANCER CELL CULTURE; CELL VIABILITY; COLON CARCINOMA; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DRUG TARGETING; IN VITRO STUDY; IN VIVO STUDY; LIVER METASTASIS; LUNG METASTASIS; MOUSE; NONHUMAN; OLIGOMERIZATION; PROTEIN EXPRESSION; RECEPTOR BINDING; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, NEOPLASM; APOPTOSIS; CAMELIDS, NEW WORLD; CELL LINE, TUMOR; COLONIC NEOPLASMS; HEK293 CELLS; HETEROGRAFTS; HUMANS; LIVER NEOPLASMS; MICE; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; RECEPTORS, TUMOR NECROSIS FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84892158338     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.26709     Document Type: Article

References (35)

1. Burkly LC, Michaelson JS, Zheng TS. TWEAK/ Fn14 pathway: an immunological switch for shaping tissue responses. Immunol Rev 2011; 244:99-114; PMID:22017434; http://dx.doi. org/10.1111/j.1600-065X.2011.01054.x
2. Winkles JA. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov 2008; 7:411-25; PMID:18404150; http://dx.doi.org/10.1038/nrd2488 (Pubitemid 351619113)
3. Ikner A, Ashkenazi A. TWEAK induces apoptosis through a death-signaling complex comprising receptor-interacting protein 1 (RIP1), Fas-associated death domain (FADD), and caspase-8. J Biol Chem 2011; 286:21546-54; PMID:21525013; http://dx.doi. org/10.1074/jbc.M110.203745
4. Schneider P, Schwenzer R, Haas E, Mühlenbeck F, Schubert G, Scheurich P, Tschopp J, Wajant H. TWEAK can induce cell death via endogenous TNF and TNF receptor 1. Eur J Immunol 1999; 29:1785-92; PMID:10382740; http://dx.doi.org/10.1002/ (SICI )1521-4141(199906)29:06<1785: :AIDIMMU1785> 3.0.CO;2-U (Pubitemid 29265533)
5. Wicovsky A, Salzmann S, Roos C, Ehrenschwender M, Rosenthal T, Siegmund D, Henkler F, Gohlke F, Kneitz C, Wajant H. TNF-like weak inducer of apoptosis inhibits proinflammatory TNF receptor-1 signaling. Cell Death Differ 2009; 16:1445-59; PMID:19557010; http://dx.doi.org/10.1038/ cdd.2009.80
6. Roos C, Wicovsky A, Müller N, Salzmann S, Rosenthal T, Kalthoff H, Trauzold A, Seher A, Henkler F, Kneitz C, et al. Soluble and transmembrane TNF-like weak inducer of apoptosis differentially activate the classical and noncanonical NF-kappa B pathway. J Immunol 2010; 185:1593-605; PMID:20610643; http://dx.doi.org/10.4049/ jimmunol.0903555
7. Salzmann S, Seher A, Trebing J, Weisenberger D, Rosenthal A, Siegmund D, Wajant H. Fibroblast growth factor inducible (Fn14)-specific antibodies concomitantly display signaling pathway-specific agonistic and antagonistic activity. J Biol Chem 2013; 288:13455-66; PMID:23532848; http://dx.doi. org/10.1074/jbc.M112.435917
8. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986; 315:1650-9; PMID:3537791; http://dx.doi.org/10.1056/ NEJM198612253152606 (Pubitemid 17052899)
9. Bhatnagar S, Kumar A. The TWEAK-Fn14 system: breaking the silence of cytokine-induced skeletal muscle wasting. Curr Mol Med 2012; 12:3-13; PMID:22082477; http://dx.doi. org/10.2174/156652412798376107
10. Dohi T, Burkly LC. The TWEAK/Fn14 pathway as an aggravating and perpetuating factor in inflammatory diseases: focus on inflammatory bowel diseases. J Leukoc Biol 2012; 92:265-79; PMID:22672874; http://dx.doi.org/10. 1189/jlb.0112042
11. Michaelson JS, Wisniacki N, Burkly LC, Putterman C. Role of TWEAK in lupus nephritis: a bench-tobedside review. J Autoimmun 2012; 39:130-42; PMID:22727560; http://dx.doi.org/10.1016/j. jaut.2012.05.003
12. Nazeri A, Heydarpour P, Sadaghiani S, Sahraian MA, Burkly LC, Bar-Or A. A Further TWEAK to Multiple Sclerosis Pathophysiology. [Epub ahead of print]. Mol Neurobiol 2013; PMID:23873135; http://dx.doi.org/10.1007/s12035-013-8490-y
13. Wajant H. The TWEAK-Fn14 system as a potential drug target. [Epub ahead of print]. Br J Pharmacol 2013; 170:748-64; PMID:23957828; http://dx.doi. org/10.1111/bph.12337
14. Ren MY, Sui SJ. The role of TWEAK/Fn14 in cardiac remodeling. Mol Biol Rep 2012; 39:9971-7; PMID:22752727; http://dx.doi.org/10.1007/ s11033-012-1867-6
15. Wisniacki N, Amaravadi L, Galluppi GR, Zheng TS, Zhang R, Kong J, Burkly LC. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Anti-TWEAK Monoclonal Antibody in Patients With Rheumatoid Arthritis. Clin Ther 2013; 35:1137-49; PMID:23928094; http://dx.doi.org/10.1016/j. clinthera.2013.06.008
16. Echeverry R, Wu F, Haile WB, Wu J, Yepes M. The cytokine tumor necrosis factor-like weak inducer of apoptosis and its receptor fibroblast growth factor-inducible 14 have a neuroprotective effect in the central nervous system. J Neuroinflammation 2012; 9:45; PMID:22394384; http://dx.doi. org/10.1186/1742-2094-9-45
17. Vázquez-Carballo A, Ceperuelo-Mallafré V, Chacón MR, Maymó-Masip E, Lorenzo M, Porras A, Vendrell J, Fernández-Veledo S. TWEAK prevents TNF-?-induced insulin resistance through PP2A activation in human adipocytes. Am J Physiol Endocrinol Metab 2013; 305:E101-12; PMID:23651848; http:// dx.doi.org/10.1152/ajpendo.00589.2012
18. Wu F, Guo L, Jakubowski A, Su L, Li WC, Bonner-Weir S, Burkly LC. TNF-Like Weak Inducer of Apoptosis (TWEAK) Promotes Beta Cell Neogenesis from Pancreatic Ductal Epithelium in Adult Mice. PLoS One 2013; 8:e72132; PMID:23991053; http:// dx.doi.org/10.1371/journal.pone.0072132
19. Bird TG, Lu WY, Boulter L, Gordon-Keylock S, Ridgway RA, Williams MJ, Taube J, Thomas JA, Wojtacha D, Gambardella A, et al. Bone marrow injection stimulates hepatic ductular reactions in the absence of injury via macrophage-mediated TWEAK signaling. Proc Natl Acad Sci U S A 2013; 110:6542-7; PMID:23576749; http://dx.doi.org/10.1073/ pnas.1302168110
20. Michaelson JS, Amatucci A, Kelly R, Su L, Garber E, Day ES, Berquist L, Cho S, Li Y, Parr M, et al. Development of an Fn14 agonistic antibody as an anti-tumor agent. MAbs 2011; 3:362-75; PMID:21697654; http://dx.doi.org/10.4161/ mabs.3.4.16090
21. Tran NL, McDonough WS, Savitch BA, Fortin SP, Winkles JA, Symons M, Nakada M, Cunliffe HE, Hostetter G, Hoelzinger DB, et al. Increased fibroblast growth factor-inducible 14 expression levels promote glioma cell invasion via Rac1 and nuclear factor-kappaB and correlate with poor patient outcome. Cancer Res 2006; 66:9535-42; PMID:17018610; http://dx.doi.org/10.1158/0008-5472.CAN-06- 0418 (Pubitemid 44623652)
22. Culp PA, Choi D, Zhang Y, Yin J, Seto P, Ybarra SE, Su M, Sho M, Steinle R, Wong MH, et al. Antibodies to TWEAK receptor inhibit human tumor growth through dual mechanisms. Clin Cancer Res 2010; 16:497-508; PMID:20068083; http://dx.doi. org/10.1158/1078-0432.CCR-09-1929
23. Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, Chan C, Chung HS, Eivazi A, Yoder SC, et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A 2006; 103:4005-10; PMID:16537476; http://dx.doi. org/10.1073/pnas.0508123103
24. Armour KL, Clark MR, Hadley AG, Williamson LM. Recombinant human IgG molecules lacking Fcgamma receptor I binding and monocyte triggering activities. Eur J Immunol 1999; 29:2613-24; PMID:10458776; http://dx.doi.org/10.1002/ (SICI )1521-4141(199908)29: 08<2613: :AIDIMMU2613> 3.0.CO;2-J (Pubitemid 29378132)
25. Chicheportiche Y, Bourdon PR, Xu H, Hsu YM, Scott H, Hession C, Garcia I, Browning JL. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem 1997; 272:32401-10; PMID:9405449; http:// dx.doi.org/10.1074/jbc.272.51.32401 (Pubitemid 28011923)
26. Nakayama M, Ishidoh K, Kayagaki N, Kojima Y, Yamaguchi N, Nakano H, Kominami E, Okumura K, Yagita H. Multiple pathways of TWEAKinduced cell death. J Immunol 2002; 168:734-43; PMID:11777967 (Pubitemid 34049574)
27. Riedel SS, Mottok A, Brede C, Bäuerlein CA, Jordán Garrote AL, Ritz M, Mattenheimer K, Rosenwald A, Einsele H, Bogen B, et al. Non-invasive imaging provides spatiotemporal information on disease progression and response to therapy in a murine model of multiple myeloma. PLoS One 2012; 7:e52398; PMID:23300660; http://dx.doi.org/10.1371/journal. pone.0052398
28. Perper SJ, Browning B, Burkly LC, Weng S, Gao C, Giza K, Su L, Tarilonte L, Crowell T, Rajman L, et al. TWEAK is a novel arthritogenic mediator. J Immunol 2006; 177:2610-20; PMID:16888023 (Pubitemid 44201020)
29. Vincent C, Findlay DM, Welldon KJ, Wijenayaka AR, Zheng TS, Haynes DR, Fazzalari NL, Evdokiou A, Atkins GJ. Pro-inflammatory cytokines TNFrelated weak inducer of apoptosis (TWEAK) and TNFalpha induce the mitogen-activated protein kinase (MAPK)-dependent expression of sclerostin in human osteoblasts. J Bone Miner Res 2009; 24:1434-49; PMID:19292615; http://dx.doi.org/10.1359/ jbmr.090305
30. Lam ET, Eckhardt SG, Messersmith W, Jimeno A, O'Bryant CL, Ramanathan RK, et al. Abstract C18: A phase I study of enavatuzumab (PDL192, ABT-361), a first-in-class human monoclonal antibody targeting TWEAK (tumor necrosis factor-like inducer of apoptosis) receptor, in patients (Pts) with advanced solid tumors. Mol Cancer Ther 2011; 10:C18; http:// dx.doi.org/10.1158/1535- 7163.TARG-11-C18
31. Culp, P (2009) Therapeutic use of anti-TWEAK antibodies WO2009020933A2.
32. Garber, E., Burkly, L., Michealson, J., Lugovskoy, A., Hsu, Y.-M., and Hanf, K. (2009) Anti-Fn14 antibodies and uses thereof. WO2009140177A2.
33. de Haard HJ, van Neer N, Reurs A, Hufton SE, Roovers RC, Henderikx P, de Bruïne AP, Arends JW, Hoogenboom HR. A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies. J Biol Chem 1999; 274:18218-30; PMID:10373423; http://dx.doi.org/10.1074/jbc.274.26.18218
34. Thalheimer A, Otto C, Bueter M, Illert B, Gattenlohner S, Gasser M, Meyer D, Fein M, Germer CT, Waaga-Gasser AM. The intraportal injection model: a practical animal model for hepatic metastases and tumor cell dissemination in human colon cancer. BMC Cancer 2009; 9:29; PMID:19166621; http://dx.doi.org/10. 1186/1471-2407-9-29
35. Thalheimer A, Korb D, Bönicke L, Wiegering A, Mühling B, Schneider M, Koch S, Riedel SS, Germer CT, Beilhack A, et al. Noninvasive visualization of tumor growth in a human colorectal liver metastases xenograft model using bioluminescence in vivo imaging. J Surg Res 2013; In press; PMID:23998649; http://dx.doi.org/10.1016/j.jss.2013.03.024.